EXTENDED INDUCTION IN THE TRUE NORTH OPEN-LABEL EXTENSION STUDY: CLINICAL OUTCOMES OF ∼2 YEARS OF OZANIMOD TREATMENT

被引：0
|
作者：
Rubin, David T.
Colombel, Jean Frederic
Chiorean, Michael V.
Ghosh, Subrata
Jain, Anjali
Lawlor, Garrett
Osterman, Mark T.
Wu, Hsiuanlin
Canavan, James B.
Vermeire, Severine
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1736
引用
收藏
页码：S1102 / S1102
页数：1
相关论文
共 50 条
  • [1] Extended induction in the True North open-label extension study: clinical outcomes of ∼2 years of ozanimod treatment
    Vermeire, S.
    Colombel, J. F.
    Chiorean, M. V.
    Ghosh, S.
    Jain, A.
    Lawlor, G.
    Osterman, M. T.
    Wu, H.
    Canavan, J. B.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 903 - 904
  • [2] Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study
    Abreu, Maria T.
    Dulai, Parambir
    Dignass, Axel
    Savarino, Edoardo
    Hudesman, David
    Afzali, Anita
    Jairath, Vipul
    Osterman, Mark
    Akukwe, Lucy
    Liu, W. Jerry
    Memaj, Arteid
    Petersen, AnnKatrin
    Jain, Anjali
    Canavan, James B.
    Vermeire, Severine
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S537 - S537
  • [3] Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    Danese, S.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : I101 - I102
  • [4] Efficacy and safety of 3 years of continuous ozanimod treatment: An interim analysis of the True North open-label extension study
    Danese, S.
    Sparrow, M.
    Abreu, M. T.
    Wolf, D. C.
    Canavan, J. B.
    Jain, A.
    Wu, H.
    Petersen, A.
    Charles, L.
    Panaccione, R.
    Afzali, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 121 - 122
  • [5] Efficacy and safety of 4 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study
    D'Haens, G.
    Sands, B. E.
    Ferrante, M.
    Matsuoka, K.
    Lindsay, J. O.
    Blumenstein, I.
    Mehra, D.
    Charles, L.
    Cetin, V.
    Petersen, A.
    Wu, H.
    Wang, D.
    Jain, A.
    Hanauer, S. B.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1814 - I1815
  • [6] Long-Term Clinical and Endoscopic Outcomes in True North Week 52 Clinical Remitters Over 3 Years of Treatment With Ozanimod: An Interim Analysis of the True North Open-Label Extension Study
    Afzali, Anita
    Rubin, David T.
    Abreu, Maria T.
    Chiorean, Michael V.
    Akukwe, Lucy
    Jain, Anjali
    Petersen, AnnKatrin
    Osterman, Mark T.
    Wu, Hsiuanlin
    Danese, Silvio
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S630 - S631
  • [7] Extended induction in the True North open-label extension study: Ozanimod efficacy in biologic-naive and biologic-experienced patients
    Dignass, A.
    Sparrow, M.
    Regueiro, M.
    Colombel, J-F
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Vermeire, S.
    Rubin, D. T.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 120 - 121
  • [8] Durability of recaptured response to ozanimod during the True North open-label extension
    Dignass, A.
    Regueiro, M.
    Colombel, J. F.
    Jain, A.
    Canavan, J. B.
    Wu, H.
    Lawlor, G.
    Osterman, M. T.
    Vermeire, S.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 817 - 818
  • [9] EXTENDED THERAPY WITH OZANIMOD FOR DELAYED RESPONDERS TO OZANIMOD IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: DATA FROM THE TRUE NORTH OPEN-LABEL EXTENSION STUDY
    Panaccione, Remo
    Afzali, Anita
    Hudesman, David
    Lawlor, Garrett
    Osterman, Mark T.
    Eren, Devrim
    Memaj, Arteid
    Regueiro, Miguel D.
    Ghosh, Subrata
    GASTROENTEROLOGY, 2022, 162 (07) : S965 - S965
  • [10] Achievement and maintenance of endoscopic, histologic, and combined outcomes after extended induction in Week 10 nonresponders of ozanimod: 2-year interim analysis of the True North open-label extension study
    Vermeire, S.
    Colombel, J. F.
    Rubin, D. T.
    Ghosh, S.
    Jain, A.
    Lawlor, G.
    Osterman, M. T.
    Wu, H.
    Canavan, J. B.
    Chiorean, M. V.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 844 - 845
12345